Oncology

Back to articles

New Radioimmunotherapies Effective in Refractory Non-Hodgkin’s Lymphoma

KEY POINT

Patients with low-grade and transformed low-grade non-Hodgkin’s lymphoma (LG NHL) have historically had poor prognoses, but that situation may soon improve. Under review at FDA are a pair of agents that combine monoclonal antibodies with radionuclides, and a published study of one of the agents contains promising results. Because of their unique characteristics, these agents offer opportunities for nuclear pharmacists to expand their pharmaceutical care practices.

SOURCES

Kaminski MS et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin’s lymphoma. J Clin Oncol. 2001;19:3918–28.

Augustine SC et al. The nuclear pharmacist’s role in tositumomab and 131I tositumomab–combination therapy for non-Hodgkin’s lymphoma: opportunity for pharmaceutical care in a specialty practice. J Am Pharm Assoc. In press.